The Impact of Residential Racial Segregation on Non-Small Cell Lung Cancer Treatment and Outcomes

被引:27
|
作者
Annesi, Chandler A.
Poulson, Michael R.
Mak, Kimberley S.
Tapan, Umit
Dechert, Tracey A.
Litle, Virginia R.
Suzuki, Kei
机构
[1] Boston Univ, Sch Med, Boston, MA 02118 USA
[2] Boston Univ, Med Ctr, Dept Surg, Boston, MA USA
[3] Boston Univ, Med Ctr, Dept Radiat Oncol, Boston, MA USA
[4] Boston Univ, Med Ctr, Dept Internal Med Hematol & Oncol, Boston, MA USA
[5] Boston Univ, Med Ctr, Div Acute Care & Trauma Surg Surg Crit Care, Dept Surg, Boston, MA USA
[6] Boston Univ, Med Ctr, Dept Surg, Div Thorac Surg, Boston, MA USA
来源
ANNALS OF THORACIC SURGERY | 2022年 / 113卷 / 04期
关键词
STAGE; RACE;
D O I
10.1016/j.athoracsur.2021.04.096
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Despite decreases in lung cancer incidence, racial disparities in diagnosis and treatment persist. Residential segregation and structural racism have effects on socioeconomic status for black people, affecting health care access. This study aims to determine the impact of residential segregation on racial disparities in non-small cell lung cancer (NSCLC) treatment and mortality. METHODS Patient data were obtained from Surveillance, Epidemiology, and End Results Program database for black and white patients diagnosed with NSCLC from 2004-2016 in the 100 most populous counties. Regression models were built to assess outcomes of interest: stage at diagnosis and surgical resection of disease. Predicted margins assessed impact of index of dissimilarity (IoD) on these disparities. Competing risk regressions for black and white patients in highest and lowest quartiles of IoD were used to assess cancer-specific mortality. RESULTS Our cohort had 193,369 white and 35,649 black patients. Black patients were more likely to be diagnosed at advanced stage than white patients, with increasing IoD. With increasing IoD, black patients were less likely to undergo surgical resection than white patients. Disparities were eliminated at low IoD. Black patients at high IoD had lower cancer-specific survival. CONCLUSIONS Black patients were more likely to present at advanced disease, were less likely to receive surgery for early stage disease, and had higher cancer-specific mortality at higher IoD. Our findings highlight the impact of structural racism and residential segregation on NSCLC outcomes. Solutions to these disparities must come from policy reforms to reverse residential segregation and deleterious socioeconomic effects of discriminatory policies. (c) 2022 by The Society of Thoracic Surgeons
引用
收藏
页码:1291 / 1298
页数:8
相关论文
共 50 条
  • [31] OUTCOMES OF RADICAL TREATMENT OF EARLY STAGE NON-SMALL CELL LUNG CANCER
    Yap, C.
    Hakendorf, P.
    Woodman, R.
    Lance, D.
    Leung, J.
    D'Costa, J.
    Bowden, J.
    Rose, A.
    RESPIROLOGY, 2015, 20 : 38 - 38
  • [32] Impact of Heart and Lung Radiation Dose and Lymphopenia on Non-Small Cell Lung Cancer Outcomes
    Little, J.
    Ahmad, S.
    Skwarski, M.
    Smith, D.
    Taylor, B.
    Vasiliadou, I.
    Vivekanandan, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S901 - S902
  • [33] Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer
    Brouchet, Laurent
    Bauvin, Eric
    Marcheix, Bertrand
    Bigay-Game, Laurence
    Renaud, Claire
    Berjaud, Jean
    Falcoze, Pierre Emmanuel
    Venissac, Nicolas
    Raz, Dan
    Jablons, David
    Mazieres, Julien
    Dahan, Marcel
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : 626 - 631
  • [34] Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer
    Perez, EA
    CHEST, 1998, 114 (02) : 593 - 604
  • [35] Non-small cell lung cancer at the extremes of age: Impact on diagnosis and treatment
    Nugent, WC
    Edney, MT
    Hammerness, PG
    Dain, BJ
    Maurer, LH
    Rigas, JR
    ANNALS OF THORACIC SURGERY, 1997, 63 (01): : 193 - 197
  • [36] Racial Diversity of Actionable Mutations in Non-Small Cell Lung Cancer
    Bollig-Fischer, Aliccia
    Chen, Wei
    Gadgeel, Shirish M.
    Wenzlaff, Angela S.
    Cote, Michele L.
    Schwartz, Ann G.
    Bepler, Gerold
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 250 - 255
  • [37] Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care
    Hamid, Safraz A.
    Lee, Do H.
    Herrin, Jeph
    Yu, James B.
    Pollack, Craig E.
    Dean, Lorraine T.
    Gaddy, Jacquelyne J.
    Oladele, Carol R.
    Feder, Shelli L.
    Canavan, Maureen E.
    Nunez-Smith, Marcella
    Soulos, Pamela R.
    Gross, Cary P.
    CANCER MEDICINE, 2025, 14 (05):
  • [38] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [39] On the pharmacogenetics of non-small cell lung cancer treatment
    Santarpia, Mariacarmela
    Rolfo, Christian
    Peters, G. J.
    Leon, Leticia G.
    Giovannetti, Elisa
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317
  • [40] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409